HOWL

$0.39+$0.00 (+1.07%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$18.6M

49M shares

52-week range

$0.27 – $2.38

5% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-13.50

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$8M	+230.4%	$-0.89	$-1.05–$-0.73	—	1
2027	$3M	-62.8%	$-1.59	$-1.59–$-1.59	—	1
2028	$50000	-98.4%	$-1.47	$-1.47–$-1.47	—	1
2029	$18M	+35900.0%	$-0.98	$-0.98–$-0.98	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 7 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-07-31	$-0.28	$0.08	+128.6%
2026-05-07	$-0.32	$-0.28	+12.5%
2026-03-27	$-0.34	$-0.20	+41.2%
2025-11-04	$-0.39	$-0.36	+7.7%
2025-08-14	$-0.50	$-0.40	+20.0%
2025-05-08	$-0.44	$-0.40	+9.1%
2025-03-11	$-0.43	$-0.46	-7.0%
2024-11-07	$-0.41

DCF fair valuemodel estimate

Intrinsic value

$1.02

Price

$0.39

Implied upside

+165%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
HOWLWerewolf Therapeutics, Inc.	$0.39	+1.07%	$19M	—
ACETAdicet Bio, Inc.	$8.26	+0.00%	$77M	—
CUECue Biopharma, Inc.	$31.08	+2.17%	$82M	—
INMBINmune Bio, Inc.	$2.08	+1.96%	$55M	—
IOBTIO Biotech, Inc.	$0.01	-27.59%

Werewolf Therapeutics, Inc. Common Stock

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.

www.werewolftx.com

Employees: 14
IPO / List date: Apr 30, 2021
HQ: WATERTOWN, MA

Held by traders on TradeandTell

No one on the platform currently holds HOWL.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	516,218	$429.8K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded HOWL yet.

$HOWL chatter on StockTwits

Dan@skyrockets_Inc1d
$HOWL Buying 100k more over the course of the rest of this week.
View on StockTwits ↗
zawojak@zawojakBearish2d
$HOWL my opinion this will suddenly rs and f up all remaining longs. No other option for this POS to stay on Nasdaq.
View on StockTwits ↗
John Anthony@JA19506d
$HOWL @BiotechValues PART I: Not to be combative, but you reference ChatGPT analysis in a post below and I would just offer that I asked it to contrast the value of Howl's assets against those of $BCAB as an AI exercise. My question was generic and unbiased. And should be taken with more than a grain of salt. ChatGPT's response: Why I think BCAB could command the larger premium Several factors differentiate BioAtla: Breadth of the platform. CAB technology is applicable across multiple antibody modalities, creating more optionality than a cytokine-focused platform. Pipeline diversity. BCAB has multiple distinct assets (ADCs plus a conditionally active T-cell engager), whereas HOWL's programs are more concentrated around cytokine biology.
View on StockTwits ↗
A@DuvalFishAug 5
$HOWL on July 31st around 500-600k shares were traded premarket at .49 cents and nothing moved. This morning 150k shares traded at .425 and nothing moved. Anybody got a theory on this? That’s odd to me
View on StockTwits ↗
SwingTrades1@SwingTrades1BullishAug 4
$HOWL WTX-124 is a unique asset in the oncology landscape. If the ongoing trials are successful, it could meaningfully change the company's position. Their approach to engineering IL-2 is differentiated. They're designed to preserve CD25 receptor engagement while minimizing the vascular leakage that has historically limited IL-2 therapies for others. They now have enough cash to complete the current trial, and a positive outcome would significantly strengthen their negotiating leverage. It would also expand the number of potentially monetizable assets, allowing them to retain the platform that continues to generate new candidates rather than having to part with the underlying technology. https://aacrjournals.org/cancerimmunolres/article-abstract/14/3/434/774857/WTX-124-a-Conditionally-Activated-Wild-Type-IL2
View on StockTwits ↗
LabPsycho@LabPsychoAug 4
$HOWL @skyrockets_Inc @Biotech_Beast @BiotechValues I would like to compliment myself on this call a few days ago..HOWL drifting back up after the post quarterly report pantsing as predicted. Good luck. Hmmm....50k shares @ 0.40 or 100k at $0.24 ? Opinions? Little concerned about R/S possibility before Nov?
View on StockTwits ↗
Giuseppe@joe77wAug 4
$HOWL worth at least 1 USD when and if this scenario does materialize...🙏🤞
View on StockTwits ↗
Joel Thomson@BiotechValuesBullishAug 4
$HOWL My thoughts are the company will execute S/A in multiple waves. Explains why Piper is taking so long and heavy burn on lawyers: 1. Sell off the INDUCER TCE platform first and either keep the cash or pay some out to shareholders as dividend. 2. Get to the data in q4 on WTX-124 and WTX-330 IL programs (there must be some level of interest in those two programs or why keep paying for the trials to move forward). 3. Attempt to monetize WTX-124 and WTX-330 after q4 data. 4. With most programs sold off, execute a reverse merger with the remaining shell and issue CVRs for any remaining programs
View on StockTwits ↗
Joel Thomson@BiotechValuesBullishAug 4
$HOWL ChatGPT thinks there is a good chance there will be interest in HOWL's INDUCER TCE platform and based on the XLO precedent of $52M upfront just for an OPTION agreement (very similar TCE tech). Lots of upside potential like CBIO.
View on StockTwits ↗
Giuseppe@joe77wAug 4
$HOWL May be a new CBIO stock...😋
View on StockTwits ↗
A@DuvalFishAug 3
$CYAB news dropped this morning. Waited for the pull back. Entered at .302 and sold 75% at .57. Moving profits to $HOWL nice start to a Monday!
View on StockTwits ↗
Dan@skyrockets_IncAug 3
$HOWL Pre-clinical INDUCER program could be where the REAL value is, based on recent TCE deals (i.e. Jazz, Vertex, etc recent deals). The thesis here is that HOWL is leveraging the 124 and 330 trials to possibly sell the INDUCER molecule platform. Why INDUCER could command a premium If Werewolf's conditional masking works in humans, it could offer several advantages over conventional T-cell engagers: -Reduced cytokine release syndrome. -Less off-tumor toxicity. -Ability to dose systemically rather than relying on complex step-up dosing. -Access to tumor targets that have previously been considered too risky because they are also expressed in normal tissues. Importantly, the clinical validation of the PREDATOR linker in the INDUKINE programs reduces some technology risk for INDUCER, even though the T-cell engager candidates themselves remain preclinical/IND-enabling. Management has explicitly said it is leveraging the positive clinical experience from WTX-124 and WTX-330 to advance INDUCER.
View on StockTwits ↗
Dan@skyrockets_IncAug 3
$HOWL For those that claim that TCE is dead , Jazz just paid 56m upfront for TCE development partner https://www.fiercebiotech.com/biotech/jazz-gets-pocket-792m-biobucks-drug-deal-abcellera
View on StockTwits ↗
Dan@skyrockets_IncAug 3
$HOWL Friday was a free gift for those adding today. Smart money knows this is going back up.
View on StockTwits ↗
Scott@Chartwatcher1Aug 3
$HOWL adding here .379
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.